Skip to main content

SEVERE COUGH A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary f

Clinical Trial Grant
Duke Scholars

Administered By

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Awarded By

Boehringer Ingelheim Pharmaceuticals, Inc.

Start Date

August 29, 2024

End Date

July 11, 2029
 

Administered By

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Awarded By

Boehringer Ingelheim Pharmaceuticals, Inc.

Start Date

August 29, 2024

End Date

July 11, 2029